At the time of writing, Gyre Therapeutics Inc [GYRE] stock is trading at $8.88, up 11.84%. An important factor to consider is whether the stock is rising or falling in short-term value. The GYRE shares have gain 21.81% over the last week, with a monthly amount drifted -13.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On February 10, 2021, Piper Sandler initiated with a Overweight rating and assigned a price target of $15 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $20 on May 21, 2020. Oppenheimer initiated its recommendation with a Outperform and recommended $24 as its price target on January 04, 2019. B. Riley FBR Inc. reiterated a Buy rating for this stock on February 12, 2018, and upped its price target to $49. In a note dated February 09, 2018, Chardan Capital Markets reiterated an Buy rating on this stock and boosted its target price from $37.50 to $75.
For the past year, the stock price of Gyre Therapeutics Inc fluctuated between $6.11 and $19.00. Gyre Therapeutics Inc [NASDAQ: GYRE] shares were valued at $8.88 at the most recent close of the market.
Analyzing the GYRE fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.47 and Total Capital is 0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.21 points at the first support level, and at 7.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.26, and for the 2nd resistance point, it is at 9.64.
Ratios To Look Out For
It is important to note that Gyre Therapeutics Inc [NASDAQ:GYRE] has a current ratio of 3.32. On the other hand, the Quick Ratio is 2.99, and the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 7.25, the price to book ratio is 12.10 and price to earnings (TTM) ratio is 75.90.
Transactions by insiders
Recent insider trading involved Ma Songjiang, President, that happened on Mar 21 ’25 when 174.0 shares were sold. President, Ma Songjiang completed a deal on Mar 19 ’25 to sell 2000.0 shares. Meanwhile, President Ma Songjiang sold 2000.0 shares on Mar 20 ’25.
